

This is a draft version only. Do not submit to any funding organization. Only the final version from the History page can be submitted.

Dr. Vishal Navani

Correspondence language: English

Date of Birth: 3/15

Canadian Residency Status: Permanent Resident

Country of Citizenship: Australia, United Kingdom

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

Tom Baker Cancer Centre
1331 29 ST NW
Calgary Alberta T2N 4N2
Canada

Telephone

Work (*) 1-403-521-3688

Email

Work (*) vishal.navani@albertahealthservices.ca

Website

Corporate <https://profiles.ucalgary.ca/vishal-navani>

This is a draft version only. Do not submit to any funding organization. Only the final version from the History page can be submitted.



Protected when completed

Dr. Vishal Navani

Degrees

2015/8 - 2021/8	Post-doctorate, Membership, Royal College of Physicians Degree Status: Completed
2008/9 - 2011/8	Doctorate, Medicine, Imperial College of Science, Technology and Medicine Degree Status: Completed
2004/9 - 2008/9	Master's Equivalent, MA (Hons) Medical Sciences, University of Oxford Degree Status: Completed

Credentials

2021/8	Fellowship of the Royal Australasian College of Physicians (Medical Oncology), Royal Australasian College of Physicians
--------	---

Employment

2022/8	Assistant Professor of Medicine Medical Oncology, Medicine, The University of Calgary
2022/8	Staff Medical Oncologist Medical Oncology, Medicine, Tom Baker Cancer Centre

Affiliations

The primary affiliation is denoted by (*)

(*) 2022/8	Assistant Professor, The University of Calgary
------------	--

Publications

Journal Articles

1. Guram K, Huang J, Mouchati C, Abdallah N, Jani C, Navani V, Xie W, El Zarif T, Adib E, Gebrael G, Agarwal N, Li H, Labaki C, Labban M, Ruiz Morales JM, Choueiri TK, Chin Heng DY, Mittal A, Hansen AR, Rose BS, McKay RR. (2024). Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database. *Cancer*. 1: 2003-2013. ,
2. Stewart DJ, Bradford JP, Sehdev S, Ramsay T, Navani V, Rawson NSB, Jiang DM, Gotfrit J, Wheatley-Price P, Liu G, Kaplan A, Spadafora S, Goodman SG, Auer RAC, Batist G. (2024). New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices. *Current Oncology*. 28: 2453-2480. ,
3. Navani V, Heng DY. (2024). Immunotherapy in renal cell carcinoma. *Lancet Oncology*. 24: 1164-1166. ,

- [4.](#) Takemura K, Ernst MS, Navani V, Wells JC, Bakouny Z, Donskov F, Basappa NS, Wood LA, Meza L, Pal SK, Szabados B, Powles T, Beuselinck B, McKay RR, Lee JL, Ernst DS, Kapoor A, Yuasa T, Choueiri TK, Heng DY. (2024). Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy. *Eur Urol Oncol.* 7: 501-508. ,
- [5.](#) Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, Morris DG, Heng DY, Pabani A, Dean M, Navani V. (2024). Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. *JAMA Netw Open.* 2: e2352302. ,
- [6.](#) Mehul Gupta, Igor Stukalin, Daniel E Meyers, Daniel Y C Heng, Jose Monzon, Tina Cheng, Vishal Navani. (2024). Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study. *Front Oncol.* 14: 1-10. ,
- [7.](#) Gibson AJW, Dean ML, Litt I, Box A, Cheung WY, Navani V. (2024). Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib. *Current Oncology.* 26: 2427-2440. ,
- [8.](#) Stewart DJ, Ramsay T, Navani V, Liu G, Jiang DM, Batist G. (2024). Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies. *Journal Of Clinical Oncology.* 42: 973-974. ,
- [9.](#) Samnani S, Sachedina F, Gupta M, Guo E, Navani V. (2023). Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors. *Cancer Drug Resist.* 27: 416-429. ,
- [10.](#) Takemura K, Navani V, Ernst MS, Wells JC, Meza L, Pal SK, Lee JL, Li H, Agarwal N, Alva AS, Hansen AR, Basappa NS, Szabados B, Powles T, Tran B, Hocking CM, Beuselinck B, Yuasa T, Choueiri TK, Heng DY. (2023). Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. *J Urol.* 209: 701-709. ,
- [11.](#) Ernst MS, Navani V, Wells JC, Donskov F, Basappa N, Labaki C, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, McKay RR, Parnis F, Suarez C, Yuasa T, Lalani AK, Alva A, Bjarnason GA, Choueiri TK, Heng DY. (2023). Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. *Eur Urol.* 84: 109-116. ,
- [12.](#) Navani V, Meyers DE, Ruan Y, Boyne DJ, O'Sullivan DE, Dolter S, Grosjean HA, Stukalin I, Heng DY, Morris DG, Brenner DR, Sangha R, Cheung WY, Pabani A. (2023). Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. *Clin Lung Cancer.* 24: e152-e159. ,
- [13.](#) Meyers DE, Pasternak M, Dolter S, Grosjean HAI, Lim CA, Stukalin I, Goutam S, Navani V, Heng DY, Cheung WY, Morris DG, Pabani A. (2023). Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors. *JTO Clin Res Rep.* 24: 100482. ,
- [14.](#) Gibson AJW, Pabani A, Dean ML, Martos G, Cheung WY, Navani V. (2023). Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC. *JTO Clin Res Rep.* 10: 100460. ,
- [15.](#) Ernst MS, Navani V, Wells JC, Donskov F, Basappa N, Labaki C, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, McKay RR, Parnis F, Suarez C, Yuasa T, Lalani AK, Alva A, Bjarnason GA, Choueiri TK, Heng DY. (2023). Corrigendum to "Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. *Eur Urol.* 83: e166-e167. ,
- [16.](#) Gupta M, Stukalin I, Meyers D, Goutam S, Heng DY, Cheng T, Monzon J, Navani V. (2023). Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma. *JAMA Netw Open.* 1: e2319607. ,

- [17.](#) Stukalin I, Navani V, Gupta M, Ruan Y, Boyne DJ, O'Sullivan DE, Meyers DE, Goutam S, Sander M, Ewanchuk BW, Brenner DR, Suo A, Cheung WY, Heng DY, Monzon JG, Cheng T. (2023). Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. *Oncologist*. 7: 812-822. ,
- [18.](#) Navani V, Wells JC, Boyne DJ, Cheung WY, Brenner DM, McGregor BA, Labaki C, Schmidt AL, McKay RR, Meza L, Pal SK, Donskov F, Beuselinck B, Otiato M, Ludwig L, Powles T, Szabados BE, Choueiri TK, Heng DY. (2023). CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). *Clin Genitourin Cancer*. 21: 106.e1-106.e8. ,
- [19.](#) Navani V, Heng DY. (2022). Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review. *JAMA Oncology*. 1: 292-299. ,
- [20.](#) Gedye C, Navani V. (2022). Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes. *Biochim Biophys Acta Rev Cancer*. 1877: 188681. ,
- [21.](#) Navani V, Ernst M, Wells JC, Yuasa T, Takemura K, Donskov F, Basappa NS, Schmidt A, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, Powles T, McKay RR, Weickhardt A, Suarez C, Kapoor A, Lee JL, Choueiri TK, Heng DY. (2022). Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. *JAMA Netw Open*. 1: e2216379. ,
- [22.](#) Watson AS, Goutam S, Stukalin I, Ewanchuk BW, Sander M, Meyers DE, Pabani A, Cheung WY, Heng DY, Cheng T, Monzon JG, Navani V. (2022). Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy. *JAMA Netw Open*. 1: e2245596. ,
- [23.](#) Navani V, Graves MC, Marchetti GC, Mandalia H, Bowden NA, van der Westhuizen A. (2021). Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers. *Pharmacol Res Perspect*. 9: e00808. ,
- [24.](#) Travers A, Adler K, Blanchard G, Bonaventura T, Charlton J, Day F, Healey L, Kim S, Lombard J, Mallesara G, Mandalia H, Navani V, Nordman I, Paterson R, Plowman L, Quah GT, Scalley M, Shrestha P, Taylor B, van der Westhuizen A, Zhang B, Gedye C, Lynam J. (2021). Business as unusual: medical oncology services adapt and deliver during COVID-19. *Intern Med J*. 51: 673-681. ,
- [25.](#) Navani V, Lynam JF, Smith S, O'Neill CJ, Rowe CW. (2021). Castration failure in prostate carcinoma due to a functioning adrenocortical carcinoma. *Endocrinol Diabetes Metab Case Rep*. 1: 21-0036. ,
- [26.](#) Navani V, Graves MC, Bowden NA, Van Der Westhuizen A. (2020). Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. *Br J Clin Pharmacol*. 86: 1736-1752. ,

Book Chapters

- [1.](#) Navani V, Graves MC, Mandalia H, Hong M, van der Westhuizen A, Martin J, Bowden NA. (2022). Melanoma: An immunotherapy journey from bench to bedside. Rosenberg et al. *Cancer Treat Res*. Published, Springer, United Kingdom

Clinical Care Guidelines

1. Lead. Alberta Lung Cancer Guidelines. (2024).
Contributors: Dr. Vishal Navani, Dr. Doreen Ezeife, Dr. Charles Butts, Dr. Randeep Sangha, Dr. Desiree Hao, Dr. Don Morris
Description / Contribution Value: Lead for development of the early stage NSCLC guidelines